Rubella Clinical Trial - ProQuad® Intramuscular vs Subcutaneous

Status Completed

Clinical Trial Summary

Primary objective:

To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response rates to measles, mumps, rubella and to varicella at 42 days following the second dose of ProQuad®

Secondary objectives:

- To describe the antibody response rates to measles, mumps, rubella and varicella measured 30 days following the first dose of ProQuad® administered by IM or SC route,

- To describe the antibody titres to measles, mumps, rubella and varicella at 30 days following the first dose and at 42 days following the second dose of ProQuad® both administered by IM or SC route,

- To describe the safety profile of two doses of ProQuad® both administered by IM or SC route.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00402831
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 3
Start date	October 6, 2006
Completion date	May 11, 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04183114` - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)	Phase 2/Phase 3
Completed	`NCT00092430` - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)	Phase 3
Completed	`NCT02196285` - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella	Phase 1
Completed	`NCT00313950` - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine	Phase 4
Completed	`NCT00384397` - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers	Phase 3
Completed	`NCT00560755` - Safety Study of ProQuad® rHA in Infants (V221-037)	Phase 3
Completed	`NCT01878435` - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya	N/A
Completed	`NCT01777529` - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations	Phase 4
Terminated	`NCT00258726` - Immune Responses to Two Dose Varivax +/- MMR-II	Phase 1/Phase 2
Completed	`NCT00109278` - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)	Phase 2
Not yet recruiting	`NCT05771779` - Co-administration Study of OCV, TCV and MR	Phase 3
Completed	`NCT02880865` - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine	Phase 4
Completed	`NCT01681992` - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life	Phase 3
Completed	`NCT00751348` - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136	Phase 3
Completed	`NCT01702428` - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age	Phase 3
Completed	`NCT00969436` - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM	Phase 3
Completed	`NCT00566527` - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)	Phase 3
Completed	`NCT00127010` - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Phase 3
Completed	`NCT00388440` - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.	Phase 4
Completed	`NCT03148990` - Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella	Phase 2/Phase 3